|
Balance Sheet Cash Flow Statement 777 Old Saw Mill River Rd. Tarrytown, NY 10591-6707 NY Tel. 914-345-7400 Fax 914-347-2113 |
Type: Public
On the web:
http://www.regeneron.com
Employees:
919
Employee growth: 34.8%
Regeneron isn't the Pentagon, but the company is fighting some serious enemies. Regeneron Pharmaceuticals develops protein-based drugs used to battle a variety of diseases and conditions, including cancer, inflammatory ailments, and eye diseases. The biotechnology company's ARCALYST treatment for rare inflammatory diseases, including Muckle-Wells Syndrome, was approved by the FDA in 2008. Regeneron is also collaborating with Sanofi-Aventis to develop candidate VEGF Trap as a possible treatment for tumors, and it is developing VEGF Trap Eye formulation (VEGF Trap-Eye) with Bayer Healthcare for treatment of eye diseases using intraocular delivery.
Key numbers for fiscal year ending December, 2008:
Sales: $238.5M
One year growth: 90.7%
Net income: ($82.7)M
Officers:
Chairman: P. Roy Vagelos
President, CEO, and Director: Leonard S. Schleifer
SVP Finance and Administration, CFO, Assistant Secretary, and Treasurer: Murray A. Goldberg
Competitors:
Abbott Labs
Amgen
Genentech
